

> Genetics and path (Nat Rev Dis Primers 2016;2:16022)


# PANCREATIC TUMORS

Genetics and path (_Nat Rev Dis Primers_ 2016;2:16022)

• Histologic types: **adenocarcinoma** (~85%), acinar cell carcinoma, endocrine tumors, cystic neoplasms (<10%); rarely, mets to pancreas (eg, lung, breast, renal cell)

• Location: ~60% in head, 15% in body, 5% in tail; in 20% diffuse infiltration of pancreas

• Mutations in adenoca.: _KRAS_ (>90%), _p16_ (80–95%), _p53_ (50–75%), _SMAD4_ (~55%)

流行病學 and risk factors (_Lancet_ 2016;388:73)

• 4th leading cause of cancer death in U.S.; 80% panc adeno in ages 60–80 y; M>F (1.3:1)

• Acquired risk factors: **smoking** (RR ~1.5; 25% cases), obesity, chronic pancreatitis, T2DM

• Hereditary (5–10%): familial breast/ovarian CA (_BRCA2_); _hereditary chronic pancreatitis_ (mutation in cationic trypsinogen gene (_PRSS1_, _SPINK1_); _familial cancer syndromes:_ atypical multiple mole melanoma (_CDKN2A/p16_), Peutz-Jeghers (_LKB1_), ataxia-telang.

臨床表現

• **Painless jaundice** (w/ pancreatic head mass), **pain** radiating to back, ↓ **weight** & appetite

• New-onset atypical DM (25%); migratory thrombophlebitis (Trousseau’s syndrome)

• Exam: RUQ/epigastric nontender mass, palpable gallbladder (Courvoisier’s sign); hepatomegaly; ascites; L supraclav. node (Virchow’s) & palpable rectal shelf (non-spec.)

• Laboratory tests may show ↑ bilirubin, ↑ alk phos, anemia

Diagnostic and staging evaluation (_NCCN Guidelines_ v.1.2019)

• **Pancreatic protocol CT scan** (I+ with arterial & venous phase imaging) or **MRI with contrast**

• _If no lesion seen_ → EUS, ERCP, or MRCP

• **Biopsy pancreatic lesion** via EUS-guided FNA (preferred in potential surgical candidates) or CT-guided (potential risk of seeding) or biopsy of possible metastasis

• ✔ **CA19-9** preop (nb, can be ↑ in benign liver/biliary dis.); may be useful to trend postop

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>臨床(Radiologic) Staging Non-Metastatic Panc Adenoca (~40% of cases)</b></p></td></tr><tr><td><p><b>Resectable</b></p></td><td><p>No extrapanc dis. or bulky LAN; no <b>arterial</b> tumor contact [celiac axis (CA), SMA, common hepatic (CHA)]; and no <b>venous</b> contact [SMV, portal vein (PV)] or ≤180<b>°</b> + patent veins (ie, no tumor thrombus)</p></td></tr><tr><td><p><b>Borderline resectable</b></p></td><td><p>No extrapanc dis. or bulky LAN. <b>Head/uncinate:</b> contact with CHA (no extension to CA or HA bifurcation), SMA contact ≤180<b>°</b>, variant anatomy.</p><p><b>Body/tail:</b> contact CA ≤180<b>°</b> or &gt;180<b>°</b> but without gastro-duodenal art. or aortic. <b>Venous:</b> SMV &amp; PV contact ≤180<b>°</b> with contour irreg; contact with IVC.</p></td></tr><tr><td><p><b>Unresect.</b></p></td><td><p><b>Distant mets</b>; or <b>head/uncinate:</b> contact &gt;180<b>°</b> SMA, CA; or <b>Body/tail:</b> contact &gt;180<b>°</b> SMA or CA; CA &amp; aortic involvement; or</p><p><b>Venous:</b> SMV/PV involvement/not reconstructible</p></td></tr></tbody></table>

治療 of pancreatic adenocarcinoma (_Lancet_ 2016;388:73)

• **Resectable:** pancreaticoduodenectomy (**Whipple procedure**) + adjuvant chemo:

modified FOLFIRINOX (5-FU + leucovorin, irinotecan, oxaliplatin) if ECOG 0-1 (_NEJM_ 2018;379:2395), otherwise gemcitabine + capecitabine (_Lancet_ 2017;389:1011). Gemcitabine monoRx used to be recent standard, but now with ↓ role. Role of RT is controversial.

• **Borderline:** goal to ↓ tumor to allow complete resection (R0 – neg margin at histology) using neoadjuvant Rx (various approaches tested). General schema: **chemo** ± **RT** → **restage & potential resection** depending on response**.** May need vasc. reconstruction during resection. Regimens include: FOLFIRINOX; gemcitabine + nab-paclitaxel.

• **Locally advanced** (ie, unresectable): Rx is typically palliative. However, in highly select 病人 recent trend toward Rx with FOLFIRINOX plus XRT followed by laparotomy for response assessment (imaging can be unreliable) and potential resection.

• **Metastatic:** _臨床trials preferred;_ Rx based on performance status (PS)

_Good PS:_ **FOLFIRINOX** (± olaparib); **gemcita.** + nab-paclitaxel (_NEJM_ 2013;369:1691)

_Poor PS:_ gemcitabine; capecitabine; continuous infusion 5-FU

• **Palliative and supportive care**

obstructive jaundice or gastric outlet obstruction: endoscopic stenting or surgical bypass

pain: opiates, celiac plexus neurolysis, XRT; wt loss: enzyme replacement, nutrition c/s

### Prognosis

• Resectable: if Rx’d with adjuvant FOLFIRINOX, 50+ mos, otherwise ~30 mos

• Unresectable: if locally advanced ~1–2 y; if metastatic, ~1 y

Cystic lesions of the pancreas (_NEJM_ 2004;351:1218; _Oncologist_ 2009;14:125)

• **Serous cystadenoma:** usually benign; central scar or honeycomb appearance on imaging

• **Mucinous cystic neoplasm** (MCN): predominantly young females; multiloculated tumors in body or tail with ovarian-type stroma and mucin-rich fluid with ↑ CEA levels; precancerous

• **Intraductal papillary mucinous neoplasm** (IPMN): arises in main panc duct or branch → ductal dilation; ? prog to CA (5–20 y); surgery based on age, size, location, dysplasia
